MiMedx

1234 Airport Road
Suite 105
Destin
Florida
32541
United States

Tel: 850-269-0000

Website: http://www.mimedx.com/

Show jobs for this employer

462 articles about MiMedx

  •  Prescience Point Capital Management, together with its affiliates ("Prescience Point"), a research-focused, catalyst-driven investment firm, announced today the nomination of four highly qualified director candidates to the Board of Directors (the "Board") of MiMedx Group, Inc.

  • MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today confirmed that Prescience Point Capital Management (“Prescience Point”) submitted a notice of nomination of Eiad Asbahi, Alfred G. Merriweather, Charlotte E. Sibley and William F. Spengler

  • MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that management will be participating in the following virtual investor conferences: H.C. Wainwright Global Life Sciences Conference Presentation: Wednesday, March 10, 2021 available to view on-demand beginning at 2:00 PM ET

  • MiMedx Group, Inc., an industry leader in advanced wound care and a therapeutic biologics company, announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th at 4:30 PM EST.

  • MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Dr. Robert Stein, Executive Vice President, Research & Development, will participate in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference held January 11-14, 2021. The pre-recorded fireside chat will be avail

  • Former MiMedx CEO Parker Petit Found Guilty of Fraud

    Parker H. “Pete” Petit, the former chief executive officer of wound care company MiMedx was convicted of fraud and making false statements to the U.S. Securities and Exchange Commission, following a months-long investigation into the company’s financial records. William Taylor, the company’s form...

  • MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, MiMedx Chief Executive Officer, and Peter M. Carlson, MiMedx Chief Financial Officer, will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020, beginning at 9:30 am, Eastern Time. A live webcast of the presentatio

  • MiMedx Group, Inc., an industry leader in advanced wound care and a therapeutic biologics company, confirmed that the Company’s common stock will commence trading on The Nasdaq Stock Market at the opening of trading on Wednesday, November 4, 2020, under the ticker symbol “MDXG”.

  • MiMedx Group, Inc., an industry leader in advanced wound care and a therapeutic biologics company, provided guidance regarding certain unaudited, preliminary third quarter financial results.

  • Research in Plantar Fasciitis Advances Understanding of Amniotic Tissue as Potential Treatment for Chronic Musculoskeletal Pain and Function Disorders MARIETTA, Ga., Sept. 17, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the conclusion of enrollment for a Phase 3 study of plantar fasciitis, an inflammation of the fibrous tissue along the botto

  • New Allograft Expands to Twice its Size and Provides a Protective Structure to Support the Wound Healing Cascade

  • MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the addition of Robert B. Stein, M.D., Ph.D., as Executive Vice President, Research and Development, effective August 10, 2020. Noted for significant contributions and accomplishments in medical research and development, Dr. Stein brings to MiMedx more than 40 years of drug disc

  • MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (“ SEC ”) in connection with its upcoming 2019 annual meeting of shareholders (“ Annual Meeting ”). The meeting is scheduled to be held on August 31, 2020 at 10:00 a.m. Eastern Ti

  • MiMedx Group, Inc., an industry leader in advanced wound care and an emerging therapeutic biologics company, announced the addition of Rohit Kashyap, Ph.D., as Executive Vice President and Chief Commercial Officer, effective August 3, 2020.

  • MiMedx Group, Inc., an industry leader in advanced wound care and an emerging therapeutic biologics company, announced the filing of its 2020 first quarter Form 10-Q.

  • MiMedx Group, Inc., an industry leader in advanced wound care and an emerging therapeutic biologics company, announced the filing of its 2019 Annual Report.

  • Equity Financing Led by EW Healthcare Partners and Debt Financing Provided by Hayfin Capital Management EW Healthcare Partners Managing Director and Co-Founder Martin Sutter and Former Medtronic Chairman and CEO William Hawkins to Join MiMedx Board of Directors MARIETTA, Ga., July 02, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the closing

  • MiMedx Group, Inc., an industry leader in advanced wound care and an emerging therapeutic biologics company, announced that it is repaying the Payment Protection Program Loan received through its application to the Federal relief effort.

  • MiMedx Group, Inc., an industry leader in advanced wound care and an emerging therapeutic biologics company, announced that Peter M. Carlson, Executive Vice President of Finance, has been named as the Company's Chief Financial Officer, effective immediately..

  • MiMedx Group, Inc. announced the filing of its 2018 Annual Report, which includes the Company's audited consolidated statements of operations, and stockholders' equity and cash flows for the years ended December 31, 2018 and 2017, which the Company did not previously file, and for the year ended December 31, 2016, which the Company has restated.